Bluejay Diagnostics (BJDX) reports Q2 2026 results
Bluejay Diagnostics (BJDX) reports Q2 2026 results, citing a strengthened balance sheet that supports advancing Symphony™ IL-6 toward regulatory submission and commercialization.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.